In:
Frontiers in Genetics, Frontiers Media SA, Vol. 13 ( 2022-5-11)
Abstract:
Lung adenocarcinoma (LUAD) is one of the most common malignancies with the highest mortality globally, and it has a poor prognosis. Cell cycle checkpoints play a central role in the entire system of monitoring cell cycle processes, by regulating the signalling pathway of the cell cycle. Cell cycle checkpoints related genes (CCCRGs) have potential utility in predicting survival, and response to immunotherapies and chemotherapies. To examine this, based on CCCRGs, we identified two lung adenocarcinoma subtypes, called cluster1 and cluster2, by consensus clustering. Enrichment analysis revealed significant discrepancies between the two subtypes in gene sets associated with cell cycle activation and tumor progression. In addition, based on Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression, we have developed and validated a cell cycle checkpoints-related risk signature to predict prognosis, tumour immune microenvironment: (TIME), immunotherapy and chemotherapy responses for lung adenocarcinoma patients. Results from calibration plot, decision curve analysis (DCA), and time-dependent receiver operating characteristic curve (ROC) revealed that combining age, gender, pathological stages, and risk score in lung adenocarcinoma patients allowed for a more accurate and predictive nomogram. The area under curve for lung adenocarcinoma patients with 1-, 3-, 5-, and 10-year overall survival was: 0.74, 0.73, 0.75, and 0.81, respectively. Taken together, our proposed 4-CCCRG signature can serve as a clinically useful indicator to help predict patients outcomes, and could provide important guidance for immunotherapies and chemotherapies decision for lung adenocarcinoma patients.
Type of Medium:
Online Resource
ISSN:
1664-8021
DOI:
10.3389/fgene.2022.908104
DOI:
10.3389/fgene.2022.908104.s001
DOI:
10.3389/fgene.2022.908104.s002
DOI:
10.3389/fgene.2022.908104.s003
DOI:
10.3389/fgene.2022.908104.s004
DOI:
10.3389/fgene.2022.908104.s005
DOI:
10.3389/fgene.2022.908104.s006
DOI:
10.3389/fgene.2022.908104.s007
DOI:
10.3389/fgene.2022.908104.s008
DOI:
10.3389/fgene.2022.908104.s009
DOI:
10.3389/fgene.2022.908104.s010
DOI:
10.3389/fgene.2022.908104.s011
DOI:
10.3389/fgene.2022.908104.s012
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2606823-0
Bookmarklink